Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sens. Hatch, Alexander Expected To Helm Health Panels In Senate

Executive Summary

Orrin Hatch, the veteran of major pharmaceutical legislative initiatives, is in line to head the Finance Committee with the change to Republican control of the Senate. The Health, Education, Labor and Pensions Committee – with jurisdiction over biomedical R&D and public health – will be headed by Lamar Alexander, in his first opportunity to chair a committee.

You may also be interested in...



IPAB’s Tough Road Ahead Shown As Republicans Opt Not To Help Find Members

House Speaker Boehner and Senate Majority Leader McConnell “respectfully decline” the president’s request to submit names of individuals to serve on the Medicare Independent Payment Advisory Board.

Senior Senators Seek Details On Government Audits Of 340B Entities

Top Republicans on two Senate health committees are joined by House members in seeking answers on an HHS review of entities receiving 340B drug discounts, including the process and consequences of audits and decertification.

Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA

Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS056464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel